Publications by authors named "Rumiko Nogami"
Background: Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy of peripheral T-lymphocytes and its prognosis still remains very poor.
Materials And Methods: The potential of combining the Bcl-2 homology 3 mimetic ABT-737, which blocks Bcl-2, Bcl-XL, and Bcl-w, with either the proteasome inhibitor bortezomib or histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) to inhibit the growth of human T-lymphotropic virus type-I (HTLV-1) infected T-cell lines and its mechanism was further evaluated.
Results: ABT-737 synergistically induced apoptosis when combined with either bortezomib or SAHA in HTLV-1 infected T-cell lines and fresh ATL cells.
Article Synopsis
- Adult T-cell leukemia/lymphoma (ATL) is a serious cancer linked to the human T-cell lymphotropic virus type I, and previous research identified several plant extracts that may inhibit ATL cell growth.
- Researchers tested additional withanolides from solanaceous plants to investigate their effects on ATL cells, finding that certain chemical groups, specifically a 4β-hydroxy and a 5β,6β-epoxy group, were crucial for effectiveness, while sugar components at specific positions decreased activity.
- Among the tested compounds, 24,25-dihydrowithanolide D was highlighted as the most effective, promoting cell death specifically in ATL cell lines through apoptosis.
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-lymphotropic virus type I (HTLV-1). ABT-737, a small molecule inhibitor of Bcl-2, Bcl-X(L), and Bcl-w, significantly induced apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells, and synergistically enhanced the cytotoxicity and apoptosis induced by conventional cytotoxic drugs. Moreover, ABT-737 significantly inhibited the in vivo tumor growth of an ATLL mouse model.
View Article and Find Full Text PDF